Rossari Biotech Limited (ROSSARI)
₹454.65 +4.00% last close, 16 Oct
Q2 FY27 results
📅 Next results: 17 Oct 2026 (board meeting)Rossari Biotech Limited's board meets on 17 Oct 2026 to consider its Q2 FY27 results (July-September 2026).
In its latest reported quarter, Q1 FY27, Rossari Biotech's revenue was ₹697 Cr (+28.2% year on year, +1.8% on the previous quarter), and net profit ₹35.1 Cr (+4.5% year on year); the operating margin was 11.6%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹697 | +28.2% | +1.8% |
| Operating profit | ₹80.6 | +18.8% | +4.7% |
| Net profit | ₹35.1 | +4.5% | -23.7% |
| EPS (₹) | 6.34 | +4.4% | -23.6% |
| Operating margin | 11.6% | — | — |
ROSSARI delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 43.75% of the ROSSARI shares traded on NSE were taken to delivery, against the stock's own 20-session average of 54.22%. The price rose 4.00% on unusually low delivery, so more of the move than usual was intraday trading.
Delivery in the last 5 sessions: 44.2% · 40.7% · 49.2% · 41.1% · 43.8%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Rossari Biotech Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate, issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited, confirms the processing, cancellation, and mutilation of share certificates received for dematerialisation within prescribed timelines. The filing is an ordinary procedural requirement and has no impact on business operations or financials.
- Compliance certificate submitted under Regulation 74(5) of SEBI Regulations, 2018
- Pertains to the quarter ended September 30, 2026
- Issued by RTA MUFG Intime India Private Limited on October 6, 2026
- Confirms mutilation and cancellation of physical share certificates upon dematerialisation
Rossari Biotech Limited has announced the closure of its trading window for Designated Persons and their immediate relatives starting October 1, 2026. This is a routine compliance measure pursuant to SEBI (Prohibition of Insider Trading) Regulations for the quarter and half-year ending September 30, 2026. The window will reopen 48 hours after the announcement of the unaudited financial results. The exact date of the board meeting to approve the results will be intimated later.
- Trading window closes on October 01, 2026
- Closure applies to Designated Persons and their immediate relatives
- Window to remain closed until 48 hours post announcement of results for period ending September 30, 2026
- Board meeting date to consider financial results will be intimated in due course
Rossari Biotech Limited has notified exchanges regarding its scheduled participation in the Anand Rathi Annual Flagship Conference (G-200 Summit 2026). The conference will take place in Mumbai on Tuesday, September 22, 2026, starting at 02:00 PM IST. The interactions will involve one-on-one and group meetings based on publicly available data, including its July 19, 2026 earnings presentation. The company clarified that no unpublished price sensitive information (UPSI) will be discussed.
- Participation scheduled for Tuesday, September 22, 2026, from 02:00 PM (IST) onwards
- Event: Anand Rathi Annual Flagship Conference G-200 Summit 2026
- Meeting format includes both One-on-One and Group sessions in Mumbai
- Discussions to rely on public earnings presentation submitted on July 19, 2026
Rossari Biotech Limited has informed the exchanges that it will participate in an analyst and institutional investor meeting on Thursday, September 17, 2026, starting at 10:00 AM IST in Mumbai. The interactions will involve one-on-one and group meetings. Discussions will rely solely on publicly available information, specifically referencing the Earnings Presentation submitted on July 19, 2026. The company confirmed that no unpublished price sensitive information (UPSI) will be disclosed.
- Meeting scheduled for Thursday, September 17, 2026, starting at 10:00 AM (IST) onwards
- Meeting format includes both One-on-One & Group sessions located in Mumbai
- Discussions based on the Q1 FY27 Earnings Presentation submitted to exchanges on July 19, 2026
- Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared
Rossari Biotech has informed the exchanges that it will no longer participate in the Nirmal Bang's Semi-Annual Investor Conference, which was scheduled for Monday, August 10, 2026. This update follows a previous intimation made by the company on August 3, 2026. The company was originally slated for both one-on-one and group meetings. Such withdrawals from investor conferences are typically administrative and do not impact the company's financial fundamentals or its TTM revenue of ₹2,396 Cr.
- Non-participation in the Nirmal Bang's Semi-Annual Investor Conference scheduled for August 10, 2026.
- Cancellation affects both One-on-One and Group meeting formats.
- Reference to the original intimation letter dated August 3, 2026.
- Company maintains its current TTM revenue base of ₹2,396 Cr and market cap of ₹2,915 Cr.
Rossari Biotech has announced its participation in Nirmal Bang's Semi-Annual Investor Conference scheduled for August 10, 2026, in Mumbai. The company will engage in one-on-one and group meetings starting at 02:00 PM IST. Discussions will be limited to publicly available information and the earnings presentation previously filed on July 19, 2026. This is a standard procedural disclosure under SEBI LODR regulations.
- Scheduled meeting date: Monday, August 10, 2026, at 02:00 PM IST
- Event: Nirmal Bang's Semi-Annual Investor Conference in Mumbai
- Format: One-on-One and Group meetings with institutional investors
- Reference: Discussions based on Earnings Presentation dated July 19, 2026
Rossari Biotech achieved its highest-ever quarterly revenue of approximately ₹700 crore in Q1 FY27, representing a 28% YoY growth. The Home, Personal Care and Performance Chemicals (HPPC) segment was the primary driver, crossing the ₹550 crore milestone. While net debt reduced to ₹248 crore from ₹280 crore in March 2026, interest costs rose to ₹11 crore as previous CAPEX projects were capitalized. Management is focusing on B2B scaling and international expansion, including a new greenfield plant in Thailand and a planned entry into Saudi Arabia.
- Consolidated revenue grew 28% YoY to reach a record quarterly run-rate of ~₹700 Cr
- HPPC segment revenue crossed the ₹550 Cr milestone, growing 28% YoY
- Net debt reduced by ₹32 Cr during the quarter to ₹248 Cr
- Interest expense increased to ₹11 Cr as term loans for completed CAPEX projects hit the P&L
- Asset monetization continued with the sale of an Andheri office for ₹10.5 Cr
Rossari Biotech concluded its 17th Annual General Meeting on July 20, 2026, where shareholders approved all eight proposed resolutions with over 99.99% majority. Key approvals include the adoption of FY26 financial statements, declaration of a dividend, and a material related party transaction (RPT) with Unitop Chemicals Private Limited. The company confirmed that dividends will be credited to eligible members within 10 working days. Additionally, the appointment and re-appointment of three directors, including two independent directors, were ratified.
- All 8 resolutions passed with a requisite majority, with most receiving over 99.99% of valid votes in favor.
- Material Related Party Transaction with Unitop Chemicals approved with 8,335,359 votes in favor (99.99% of non-promoter votes).
- Dividend for the financial year ended March 31, 2026, approved for distribution within 10 working days.
- A total of 48 shareholders attended the meeting via Video Conferencing, representing 14.87% of the total paid-up equity share capital.
- Re-appointment of Executive Chairman Mr. Edward Menezes and appointment of two Independent Directors confirmed.
Rossari Biotech has released the audio recording of its Q1 FY27 earnings conference call held on July 20, 2026. This follows the company's recent financial performance where it reported a TTM revenue of ₹2,396 Cr and a PAT of ₹149 Cr. The recording provides management's detailed commentary on quarterly operations and the progress of its 367,100 MTPA capacity utilization. This is a standard regulatory disclosure under SEBI Listing Obligations.
- Earnings conference call for Q1 FY27 was conducted on July 20, 2026
- Audio recording made available on the company website as per SEBI Regulation 30
- Company is currently operating with a total installed capacity of 367,100 MTPA
- TTM Operating Profit Margin (OPM) stands at 11.9% as of the latest reporting cycle
- Promoter holding remains stable at 68.15% as of March 2026
Rossari Biotech Limited has issued a clarification regarding its ESOP grant announced on July 18, 2026. The company corrected the number of stock options granted under the Rossari Employee Stock Option Plan 2019 from 4,000 to 5,000. This minor administrative adjustment involves an additional 1,000 options. All other terms and conditions of the original grant remain unchanged.
- Correction of stock options granted from 4,000 to 5,000
- Options granted under the Rossari Employee Stock Option Plan 2019
- Original board meeting for the grant held on July 18, 2026
- Administrative update to rectify an inadvertent clerical error
Rossari Biotech delivered a robust Q1 FY27 with consolidated revenue growing 28% YoY to Rs 697.2 crore, marking its highest-ever quarterly performance. EBITDA grew 19% to Rs 80.6 crore, although margins contracted slightly to 11.6% from 12.5% in the previous year. Net profit (PAT) saw a modest 4% increase to Rs 35.1 crore. The company also announced the establishment of a 5,000 MTPA greenfield blending facility in Thailand to strengthen its Southeast Asian presence.
- Consolidated revenue increased 28% YoY to Rs 697.2 crore, representing approximately 29% of TTM revenue.
- EBITDA reached a record Rs 80.6 crore, up 19% YoY, despite a 90 bps margin compression to 11.6%.
- All three business segments (HPPC, TSC, and AHN) showed uniform growth of 27-28% YoY.
- Established a new 5,000 MTPA greenfield blending facility in Thailand through subsidiary Unistar Thai.
- Completed the sale of the Andheri office as part of a strategy to monetize non-core assets.
Rossari Biotech reported a strong 28.2% YoY revenue growth to ₹697.2 Cr in Q1 FY27, driven by robust demand across its core HPPC, Textile, and Animal Health segments. While EBITDA grew 18.7% to ₹80.6 Cr, consolidated margins contracted by 90 bps to 11.6% due to higher operating costs and flat performance in the B2C segment. A key strategic milestone was the commissioning of a 5,000 MTPA greenfield blending facility in Thailand to serve Southeast Asia. The company also continued its non-core asset monetization by selling its Andheri office during the quarter.
- Consolidated revenue reached ₹697.2 Cr, up 28.2% YoY, representing approximately 29% of TTM revenue.
- Commissioned a new 5,000 MTPA greenfield facility in Thailand (Unistar Thai) for powders, granules, and liquids.
- Core B2B business segments (excluding B2C/Institutional) delivered a superior EBITDA margin of 14%.
- Segmental growth was broad-based: HPPC grew 28%, Textile Specialty Chemicals 28%, and Animal Health 27% YoY.
- Finance costs increased significantly by 93% YoY to ₹11.0 Cr, impacting PAT growth which was limited to 4.5%.
Rossari Biotech reported a strong year-on-year standalone performance for Q1 FY27, with revenue rising 31.8% to Rs 482.28 Cr compared to Rs 365.76 Cr in Q1 FY26. Standalone Profit After Tax (PAT) grew 30.6% YoY to Rs 34.27 Cr. However, performance weakened sequentially, with revenue down 6.5% and PAT down 37.4% from Q4 FY26 levels. The company also announced an internal restructuring to move its Saudi Arabian subsidiary under its Singapore entity to streamline global operations.
- Standalone Revenue from operations increased 31.8% YoY to Rs 482.28 Cr
- Standalone PAT grew 30.6% YoY to Rs 34.27 Cr, though it fell 37.4% sequentially from Rs 54.73 Cr in Q4 FY26
- Board approved the transfer of 100% shareholding of Rossari International Ltd (Saudi Arabia) to Rossari (Singapore) Pte. Ltd
- Granted 4,000 stock options under ESOP 2019 at an exercise price of Rs 531 per share
- Allotted 8,250 equity shares during the quarter following ESOP exercises, slightly increasing paid-up capital to Rs 11.08 Cr
Rossari Biotech's Board of Directors approved the grant of 4,000 stock options under the Rossari Employee Stock Option Plan - 2019 during its meeting on July 18, 2026. This grant follows the plan's ratification by shareholders on April 17, 2021. In the same session, the board also approved the unaudited financial results for the quarter ended June 30, 2026. Given the small number of options, the impact on the company's total equity and shareholder dilution is negligible.
- Grant of 4,000 stock options approved under the ESOP 2019 scheme
- Board meeting held on July 18, 2026, between 12:00 noon and 02:00 p.m.
- ESOP 2019 plan was previously ratified by members on April 17, 2021
- Approval of unaudited standalone and consolidated financial results for the quarter ended June 30, 2026
Rossari Biotech reported a strong Q1 FY27 (ending June 2026) with standalone revenue growing 31.8% YoY to ₹482.28 cr. Standalone PAT increased 30.6% YoY to ₹34.27 cr, though it saw a sequential decline from the ₹54.7 cr reported in the previous quarter. The company also announced an internal restructuring to move its Saudi Arabian subsidiary under its Singapore entity to simplify overseas reporting. Additionally, the board approved a small ESOP grant of 4,000 options at ₹531 per share.
- Standalone Revenue for Q1 FY27 rose to ₹482.28 cr from ₹365.76 cr in the same quarter last year.
- Standalone Profit After Tax (PAT) stood at ₹34.27 cr, representing a 30.6% growth over Q1 FY26.
- Internal restructuring approved to transfer 100% of Rossari International Limited Company (Saudi Arabia) to Rossari (Singapore) Pte. Ltd.
- Board approved the grant of 4,000 ESOP options at an exercise price of ₹531, near the current market price.
- Allotted 2,500 equity shares under the 2019 ESOP plan, marginally increasing paid-up capital to ₹11.08 cr.
Financial Performance
Revenue Growth by Segment
In Q2 FY26, total revenue grew 18% YoY to INR 586 Cr. Segment-wise, Home, Personal Care and Performance Chemicals (HPPC) grew 16% YoY to INR 454 Cr, Textile Specialty Chemicals (TSC) grew 21% YoY to INR 101 Cr, and Animal Health and Nutrition (AHN) grew 29% YoY to INR 31 Cr. This growth is driven by healthy volume expansion across all core businesses despite a subdued pricing environment.
Geographic Revenue Split
While specific regional percentages are not fully disclosed, the Far East and MENA regions contribute less than 10% of total sales. Exports have been increasing, which improves the company's natural hedge against foreign currency fluctuations.
Profitability Margins
Gross margins have remained stagnant at approximately 30% over the last three years due to global market uncertainty. PAT margin for FY24 was 7.1% (INR 130.5 Cr) compared to 6.4% (INR 106.3 Cr) in FY23. Profitability is sensitive to raw material price movements, as sharp increases cannot always be fully passed on to customers immediately.
EBITDA Margin
EBITDA margin for Q2 FY26 stood at 12.3% (INR 71.9 Cr), a decline from 13.2% in Q2 FY25. However, the core EBITDA margin (excluding institutional and B2C verticals) remained steady at approximately 15%. The decline is attributed to one-time expenses of INR 2.5 Cr and increased SG&A costs related to growth initiatives.
Capital Expenditure
The company is executing a total capex of INR 178 Cr. This includes INR 128 Cr for Unitop Chemicals to expand ethoxylation capacity and INR 50 Cr for Rossari Biotech to increase specialty chemical production and backward integration. This capex is expected to provide an asset turn of 4x at peak utilization, supporting a revenue potential of INR 3,500 Cr.
Credit Rating & Borrowing
Rossari maintains a credit rating of [ICRA]AA- (Stable) for fund-based limits (INR 147 Cr) and [ICRA]A1+ for non-fund based limits (INR 25.61 Cr). The company has a healthy credit profile with a TD/OPBDITA of 0.48x and interest coverage of 12.9x as of FY24.
Operational Drivers
Raw Materials
Key raw materials include surfactants, ethoxylates, and various specialty chemical intermediates. While specific % of total cost per material is not disclosed, raw material costs are the primary driver of the cost of goods sold, and volatility in these prices directly impacts the 30% gross margin floor.
Import Sources
The company sources raw materials both domestically and internationally. It is actively taking steps to reduce imports to mitigate forex risk, though specific sourcing countries like those in the Middle East or Asia are implied by the nature of chemical feedstocks.
Capacity Expansion
Current installed capacity is 367,100 MTPA across 7 manufacturing facilities. The company recently commissioned new capacities in Q2 FY26 and is further expanding ethoxylation capacity via a INR 128 Cr investment in Unitop Chemicals to meet growing demand.
Raw Material Costs
Raw material costs are susceptible to sharp fluctuations. In FY22, consolidated operating margins moderated to 11.95% from 17.35% YoY primarily due to a sharp increase in raw material costs that could not be fully passed through to the end-user.
Manufacturing Efficiency
The company targets an asset turnover ratio of 4.0x for its new capex. Efficiency is driven by 4 R&D facilities that focus on high-value-added products and process optimization.
Logistics & Distribution
Freight and traveling expenses are major components of 'other expenses,' which saw a sharp rise in Q2 FY26. Maintenance expenses also added INR 3.5 Cr to the cost base during the same period.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
Growth will be achieved by scaling up the recently commissioned 367,100 MTPA capacity, targeting a revenue potential of INR 3,500 Cr. The strategy involves focusing on high-margin B2B segments (maintaining 15% core EBITDA), expanding the ethoxylation business via Unitop, and leveraging the 26% historical revenue CAGR (FY19-25) to capture market share in HPPC and AHN.
Products & Services
Specialty chemicals for home and personal care, textile processing chemicals, animal health and nutrition supplements, surfactants, ethoxylates, and institutional cleaning sanitizers.
Brand Portfolio
Rossari, Unitop, Tristar, Romakk, Buzil (Institutional/B2C).
New Products/Services
The company has over 4,250 products and continues to launch value-added specialty chemicals. New capacity in ethoxylation is expected to contribute significantly to the HPPC segment, which already accounts for 65.1% of revenue.
Market Expansion
Expansion is focused on the Far East and MENA regions. Domestically, the company is ramping up its Dahej unit and Silvassa facilities to deepen penetration in the Indian specialty chemicals market.
Market Share & Ranking
Rossari is a leading player in the Indian textile chemical industry and has rapidly gained market share in the HPPC segment (growing from 56% to 65.1% of revenue in one year).
Strategic Alliances
Strategic investments include Romakk Chemicals and the acquisition of Unitop Chemicals and Tristar Intermediates to create synergies in surfactants and specialty intermediates.
External Factors
Industry Trends
The specialty chemicals industry is shifting toward sustainable and high-performance ingredients. Rossari is positioned to benefit from this through its R&D focus and capacity expansion in ethoxylates, which are seeing steady demand growth.
Competitive Landscape
Key competitors include large multinational corporations and domestic specialty chemical firms. Competition is particularly intense in the HPPC and textile segments, limiting the ability to raise prices aggressively.
Competitive Moat
The moat is built on technocrat promoters with 45+ years of experience, a massive portfolio of 4,250+ customized products, and deep-rooted R&D capabilities. These factors create high switching costs for B2B customers who rely on specific chemical formulations.
Macro Economic Sensitivity
The business is sensitive to global supply chain disruptions and crude oil price volatility, as many specialty chemicals are petroleum derivatives. A 10% shift in raw material costs significantly impacts the 12-13% operating margins.
Consumer Behavior
Increased demand for home and personal care products (HPPC) has shifted the revenue mix, with HPPC now representing the largest share (65.1%) of the business.
Geopolitical Risks
Uncertainty in global markets and supply chains (e.g., Far East/MENA logistics) impacts freight costs and raw material availability.
Regulatory & Governance
Industry Regulations
Operations are governed by chemical manufacturing standards, pollution control board norms, and safety regulations for hazardous material handling.
Environmental Compliance
As a chemical manufacturer, the company is subject to stringent environmental regulations regarding waste disposal and emissions. Compliance is a key operational requirement for its 7 manufacturing units.
Risk Analysis
Key Uncertainties
Project execution risk for the INR 178 Cr capex could delay the expected 4x asset turn. Raw material volatility remains the primary risk to the 15% EBITDA guidance.
Geographic Concentration Risk
Manufacturing is concentrated in Silvassa and Dahej, though the customer base is diversified across India and growing international markets.
Third Party Dependencies
Dependency on suppliers for key chemical intermediates; however, backward integration plans aim to reduce this dependency.
Technology Obsolescence Risk
The company mitigates technology risk through its 4 R&D centers and partnership with IIT Mumbai to stay at the forefront of specialty chemical formulations.
Credit & Counterparty Risk
Receivables quality is maintained through established relationships with a wide customer base, supported by a strong liquidity position and INR 172 Cr in unutilized bank limits.